What is SeraCare Life Sciences?
Founded in 1984 and headquartered in Milford, Massachusetts, SeraCare Life Sciences operates as a vital link in the discovery, development, and production of human and animal diagnostics. The company provides an essential suite of products, including quality control panels for infectious disease testing, which are indispensable to clinical laboratories, blood banks, and in vitro diagnostic (IVD) manufacturers. Beyond diagnostics, SeraCare supports the biopharmaceutical industry by supplying specialized reagents and bioprocessing materials that facilitate the creation of vaccines and complex therapeutics. With a global footprint spanning the United States, Europe, and Asia, the company leverages a robust direct sales force and a network of independent distributors to maintain its competitive edge in the life sciences market.
How much funding has SeraCare Life Sciences raised?
SeraCare Life Sciences has raised a total of $82M across 1 funding round:
Unspecified
$82M
Unspecified (2012): $82M with participation from Linden
Key Investors in SeraCare Life Sciences
Linden Capital Partners
Linden Capital Partners is a private equity firm focused on the healthcare sector, dedicated to developing middle-market healthcare and life science companies. The firm distinguishes itself through its collaborative partnerships and a comprehensive Value Creation Program, ensuring that its portfolio companies not only grow but also thrive.
What's next for SeraCare Life Sciences?
With the support of this major strategic investment, SeraCare Life Sciences is well-positioned to accelerate its growth trajectory within the bioprocessing and diagnostic quality control markets. The company is expected to prioritize the expansion of its product portfolio, focusing on high-growth areas such as molecular diagnostics and personalized medicine. By deepening its commitment to quality and regulatory excellence, SeraCare aims to enhance its value proposition for global healthcare partners. Future strategic initiatives will likely involve scaling manufacturing capabilities to meet the rising demand for reliable diagnostic standards, thereby reinforcing its status as a cornerstone of the global healthcare supply chain.
See full SeraCare Life Sciences company page
